NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Natera, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$399.42+5.98 (+1.52%)
Close on Oct 19, 2026
- Market cap
- $57.23B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$217.73 (+119.8%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Natera, Inc. grew revenue 37.8% to $2.71B over the twelve months to Jun 30, 2026. Free cash flow was $84.20M, down 19.5% from a year earlier.
Revenue
$2.71B
+37.8% vs. a year earlier
Operating income
-$289.67M
TTM Q2 2026
Free cash flow
$84.20M
-19.5% vs. a year earlier
EPS, diluted
-$1.37
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $57.23B
- P/E ratio
- –
- Price to sales
- 21.14
- Price to book
- 31.42
- Dividend yield
- –
- Free cash flow yield
- 0.15%
Fundamentals
- Revenue
- $2.71B
- Net income
- -$192.35M
- EPS, diluted
- -$1.37
- Free cash flow
- $84.20M
- Book value per share
- $12.71
- Diluted shares
- 143M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
$2.71B+37.8% YoY
Gross profit
–
Operating income
-$289.67M
Net income
-$192.35M
EPS, diluted
-$1.37
Free cash flow
$84.20M-19.5% YoY
Reported periodTrailing twelve months